Common Contracts
3 similar Underwriting Agreement contracts by Medigus Ltd., Medlab Clinical Ltd.
UNDERWRITING AGREEMENTUnderwriting Agreement • December 23rd, 2022 • Medlab Clinical Ltd. • Pharmaceutical preparations
Medlab Clinical Ltd., a company organized under the laws of Australia (the “Company”), proposes to issue and sell, to EF Hutton, division of Benchmark Investments, LLC (the “Underwriter”), an aggregate of (i) [ ] share units (the “Share Units”), with each Share Unit consisting of (A) one ordinary share (each a “Firm Share” and collectively the “Firm Shares”), no par value per share, of the Company (the “Shares”), and (B) a warrant to purchase one Share (each a “Firm Warrant” and collectively the “Firm Warrants”) and (ii) [ ] pre-funded warrant units (the “Pre-Funded Warrant Units”), with each Pre-Funded Warrant Unit consisting of (A) one pre-funded warrant to purchase one Share (the “Pre-Funded Warrants”) and (B) one Firm Warrant. The Share Units and the Pre-Funded Warrant Units, including the underlying Firm Shares, Pre-Funded Warrants and Firm Warrants are referred to herein as the “Firm Securities”. The amount and form of the Firm Securities to be purchased by the Underwriter is set
577,529 American Depositary Shares, each representing 20 Ordinary Shares Pre- Funded Warrants to Purchase 2,260,145 American Depositary Shares and Warrants to Purchase 2,837,674 American Depositary Shares Medigus Ltd. UNDERWRITING AGREEMENTUnderwriting Agreement • July 23rd, 2018 • Medigus Ltd. • Surgical & medical instruments & apparatus • New York
Medigus Ltd., an Israeli corporation (the “Company”), proposes to issue and sell to H.C. Wainwright & Co., LLC (the “Underwriter”) (i) an aggregate of (a) 577,529 American Depositary Shares of the Company (the “ADSs”), each representing twenty ordinary shares (the “Firm ADSs”), par value NIS 1.00 per share, of the Company (the “Ordinary Shares”) and (b) 2,260,145 pre-funded warrants to purchase 2,260,145 ADSs at an exercise price of $0.01 per share (the “Pre-Funded Warrants”); and (ii) 2,837,674 Series C warrants to purchase 2,837,674 ADSs (the “Firm Warrants” and, collectively with the Firm ADSs and the Pre-Funded Warrants, the “Firm Securities”). The amount and form of the Firm Securities to be purchased by the Underwriter is set forth opposite its name on Schedule I hereto. The Company also proposes to sell to the Underwriter, at the option of the Underwriter, up to an additional 425,651 ADSs (the “Option ADSs”) and/or Series C warrants to purchase up to an aggregate of 425,651 ADSs
American Depositary Shares, each representing 20 Ordinary Shares Pre-Funded Warrants to Purchase American Depositary Shares and Warrants to Purchase American Depositary Shares Medigus Ltd. UNDERWRITING AGREEMENTUnderwriting Agreement • July 18th, 2018 • Medigus Ltd. • Surgical & medical instruments & apparatus • New York
